Shalini S. Yadav - Concepedia

Author

Shalini S. Yadav

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Mayank Gupta, S Yadav, S. Yadav, Salandhri Shivani Yadav, Shalini S Yadav, Shalini S. Yadav, Shalini Singh Yadav, Shalini Yadav, Shalini S. Yadav, Shilpa Yadav

328

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Icahn School of Medicine at Mount Sinai Stony Brook University Janssen (United States)Beneficência Portuguesa de São Paulo

About

Shalini S. Yadav is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	4.5K
2	Cell Biology	4	4	504
3	Natural Sciences	2	2	94
4	Public Health	1	1	10
5	Biochemistry	1	1	60

Shalini S. Yadav

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
The Molecular Taxonomy of Primary Prostate Cancer Adam Abeshouse, Jaeil Ahn, Rehan Akbani, Cell UrologyGenitourinary CancerMedicinePathologyPrimary Prostate Cancer	2015	3.1K
MX2 is an interferon-induced inhibitor of HIV-1 infection Melissa Kane, Shalini S. Yadav, Julia Bitzegeio, Nature Human RetrovirusImmunologyAntiviral TherapyAntiviral ResponseVirology	2013	495
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma Sangeeta Goswami, Thomas Walle, Andrew Cornish, Nature Medicine Neuro-oncologyCancer ImmunosurveillanceGliomaCombinatorial TargetImmunology	2019	368
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer Jorge Blando, Anu Sharma, Maria G. Higa, Proceedings of the National Academy of Sciences	2019	317
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma Jianjun Gao, Neema Navai, Omar Alhalabi, Nature Medicine Surgical OncologyUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2020	300
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial Ahmed O. Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, The Lancet. Gastroenterology & hepatology	2022	241
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt, Nature Medicine	2023	191
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages John de Groot, Marta Peñas-Prado, Kristin Alfaro-Munoz, Neuro-Oncology	2019	158
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Science Translational Medicine	2020	155
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck Renata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, Clinical Cancer Research	2021	132

Page 1